Blair William & Co. IL decreased its position in shares of Axon Enterprise, Inc. (NASDAQ:AXON – Free Report) by 0.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 74,843 shares of the biotechnology company’s stock after selling 607 shares during the quarter. Blair William & Co. IL owned approximately 0.10% of Axon Enterprise worth $22,022,000 at the end of the most recent quarter.
Several other institutional investors have also recently made changes to their positions in AXON. Avantax Advisory Services Inc. raised its holdings in Axon Enterprise by 0.8% in the first quarter. Avantax Advisory Services Inc. now owns 5,302 shares of the biotechnology company’s stock worth $1,659,000 after purchasing an additional 40 shares in the last quarter. Brookstone Capital Management raised its stake in shares of Axon Enterprise by 5.1% during the 1st quarter. Brookstone Capital Management now owns 839 shares of the biotechnology company’s stock worth $263,000 after acquiring an additional 41 shares in the last quarter. CWM LLC lifted its position in Axon Enterprise by 1.5% during the second quarter. CWM LLC now owns 2,820 shares of the biotechnology company’s stock valued at $830,000 after acquiring an additional 43 shares during the last quarter. Wealthspan Partners LLC boosted its stake in Axon Enterprise by 4.9% in the second quarter. Wealthspan Partners LLC now owns 965 shares of the biotechnology company’s stock valued at $284,000 after acquiring an additional 45 shares in the last quarter. Finally, Burns Matteson Capital Management LLC grew its holdings in Axon Enterprise by 6.7% in the second quarter. Burns Matteson Capital Management LLC now owns 730 shares of the biotechnology company’s stock worth $215,000 after purchasing an additional 46 shares during the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.
Insider Activity
In other news, CEO Patrick W. Smith sold 80,300 shares of Axon Enterprise stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $371.78, for a total value of $29,853,934.00. Following the sale, the chief executive officer now owns 3,015,366 shares in the company, valued at $1,121,052,771.48. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Axon Enterprise news, CEO Patrick W. Smith sold 80,300 shares of the firm’s stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $371.78, for a total value of $29,853,934.00. Following the transaction, the chief executive officer now owns 3,015,366 shares in the company, valued at approximately $1,121,052,771.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michael Garnreiter sold 1,000 shares of the stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $380.99, for a total transaction of $380,990.00. Following the completion of the sale, the director now owns 27,259 shares of the company’s stock, valued at $10,385,406.41. The disclosure for this sale can be found here. Insiders sold 317,981 shares of company stock worth $115,662,734 over the last three months. 6.10% of the stock is currently owned by corporate insiders.
Axon Enterprise Price Performance
Axon Enterprise (NASDAQ:AXON – Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.18. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The firm had revenue of $504.00 million for the quarter, compared to the consensus estimate of $478.35 million. During the same period in the prior year, the firm posted $0.80 earnings per share. The firm’s quarterly revenue was up 34.5% compared to the same quarter last year. Research analysts predict that Axon Enterprise, Inc. will post 1.79 earnings per share for the current year.
Analysts Set New Price Targets
AXON has been the subject of a number of recent analyst reports. Robert W. Baird raised their price objective on Axon Enterprise from $360.00 to $400.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 10th. Craig Hallum increased their price objective on shares of Axon Enterprise from $370.00 to $376.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Bank of America initiated coverage on shares of Axon Enterprise in a research report on Wednesday, July 17th. They set a “buy” rating and a $380.00 target price on the stock. Jefferies Financial Group assumed coverage on shares of Axon Enterprise in a research note on Wednesday, July 17th. They set a “buy” rating and a $385.00 price target on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and set a $400.00 price objective on shares of Axon Enterprise in a research note on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $365.38.
View Our Latest Research Report on Axon Enterprise
Axon Enterprise Company Profile
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Further Reading
- Five stocks we like better than Axon Enterprise
- What Do S&P 500 Stocks Tell Investors About the Market?
- How Much Can You Make in Stocks in One Month?
- EV Stocks and How to Profit from Them
- This Is the Top Large-Cap Stock Insiders Are Buying
- The Most Important Warren Buffett Stock for Investors: His Own
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.